<h4>Background</h4>KN060 is a humanized dual-domain antibody targeting coagulation factor XI (FXI) and factor XIa (FXIa) and is currently being developed for the prevention of thromboembolic diseases.<h4>Objectives</h4>This study aims to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of a single intravenous administration of KN060 in healthy Chinese subjects.<h4>Methods</h4>This single-center, randomized, double-blind, placebo-controlled clinical study was conducted in 38 healthy Chinese subjects. Here, F11 is linked to Thromboembolism.